Melissa Weber

Minimizing and preventing late effects of stem cell transplantation.

Lung cancer treatment continues to make strides.

Learn tips on figuring out what causes cancer-related fatigue and how to manage it.

Calming the effects of radiation on the skin.

Studies conflict on bone-building drug's ability to prevent recurrence.

In recent years, scientists discovered that an enzyme called CYP2D6 could possibly predict whether a patient would respond to the drug. Small studies aimed at confirming the predictive link, however, have been consistently inconsistent.

Adding Afinitor, an mTOR inhibitor, to tamoxifen helped women with metastatic breast cancer live about four months longer without their disease getting worse, according to a study presented Thursday at SABCS.

Obese women with breast cancer are at higher risk for recurrence and death, but new findings suggest it may depend on cancer subtype.

New studies start to pinpoint the best strategy for treating HER2-positive breast cancer before surgery and lay the groundwork for future clinical trials.

Two studies presented at SABCS offer a better understanding of what to do with the information sentinel lymph nodes provide.

Findings from the long-awaited AZURE trial show Zometa may prevent recurrence, but not for everyone.

Not only is weight training safe, but for women who have had lymph node removal due to breast cancer surgery, it also may reduce the risk of lymphedema by about a third.

Every woman with a mutated BRCA1 or BRCA2 gene should have their ovaries removed to lower their risk of ovarian cancer, said Susan Domchek, MD, one of the educational sessions speakers at the 2010 SABCS.

New research shows some metastatic breast cancer patients could be receiving the wrong treatment.

The latest in cancer prevention, diagnosis & treatment.

Oncologists have begun trading in what had become a miracle pill for patients with chronic myeloid leukemia for more potent, newer-generation drugs that appear to work even better as first-line treatment for CML.

For patients with stage 3 colorectal cancer and normal KRAS gene activity, Erbitux (cetuximab) did not extend survival when added to chemotherapy.

Three drugs, which use different mechanisms to target cancer, highlighted at annual oncology meeting.

Researchers have developed a new screening approach that produces very few false positives in postmenopausal women with an average risk of ovarian cancer.

A new chemotherapy drug, called eribulin, extended survival by two and a half months in patients with locally recurrent or metastatic breast cancer whose cancers continued to progress despite treatment with numerous other drugs.

Continued use of the targeted drug Avastin (bevacizumab), after initial treatment with the drug and chemotherapy, helped slow progression of advanced ovarian cancer, according to a phase 3 study.

For metastatic melanoma patients who were out of treatment options, the immune system-targeted drug ipilimumab extended their lives by nearly four months compared with an investigational vaccine called gp100.